Black Diamond Therapeutics Inc (nasdaq:BDTX) Share Price

Company Profile

Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USA
T: +1 617 252-0848
https://www.blackdiamondtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.

Jacob Robbins | 21 September 2026

Morningstar analysts’ take on the takeover for this undervalued industrial player.

Esther Holloway | 20 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,951.00	31.90	0.36%
CAC 40	8,154.91	15.97	0.20%
DAX 40	25,578.85	3.84	0.02%
Dow JONES (US)	51,829.78	219.05	-0.42%
FTSE 100	10,708.33	30.68	-0.29%
HKSE	25,087.75	45.04	0.18%
NASDAQ	27,186.64	64.55	0.24%
Nikkei 225	65,018.95	882.70	1.38%
NZX 50 Index	13,875.48	54.28	0.39%
S&P 500	7,762.49	2.21	-0.03%
S&P/ASX 200	8,757.80	25.90	0.30%
SSE Composite Index	3,952.13	2.22	0.06%